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Abstract
Current drug development efforts for the treatment of atrial fibrillation are hampered
by the fact that many preclinical models have been unsuccessful in reproducing human
cardiac physiology and its response to medications. In this study, we demonstrated an
approach using human induced pluripotent stem cell-derived atrial and ventricular
cardiomyocytes (hiPSC-aCMs and hiPSC-vCMs, respectively) coupled with a sophisti-
cated optical mapping system for drug screening of atrial-selective compounds
in vitro. We optimized differentiation of hiPSC-aCMs by modulating the WNT and ret-
inoid signaling pathways. Characterization of the transcriptome and proteome rev-
ealed that retinoic acid pushes the differentiation process into the atrial lineage and
generated hiPSC-aCMs. Functional characterization using optical mapping showed
that hiPSC-aCMs have shorter action potential durations and faster Ca2+ handling
dynamics compared with hiPSC-vCMs. Furthermore, pharmacological investigation of
hiPSC-aCMs captured atrial-selective effects by displaying greater sensitivity to atrial-
selective compounds 4-aminopyridine, AVE0118, UCL1684, and vernakalant when
compared with hiPSC-vCMs. These results established that a model system incorpo-
rating hiPSC-aCMs combined with optical mapping is well-suited for preclinical drug
screening of novel and targeted atrial selective compounds.
K E YWORD S
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1 | INTRODUCTION
The advent of human induced pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs) has revolutionized the field of cardiac
research. It has enabled the study of cardiac diseases in a patient-
specific and human-relevant in vitro model system which provides a
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unique opportunity for clinical translation.1 Furthermore, the ability to
differentiate chamber-specific cardiomyocytes allows for a more pre-
cise study of cardiac disease physiology and pharmacology.
The cardiomyocytes of the lower (ventricles) and upper (atria)
chambers have distinct characteristics that arise from differential
developmental pathways. Previous work in vivo has shown that the
expression patterns of retinoic acid and retinaldehyde dehydrogenase
2 (RALDH2) are important determinants of the atrial fate.2-5 These
results were later recapitulated in a pivotal study by Lee and Protze
et al6 who determined that atrial cardiomyocytes (aCMs) differenti-
ated from human embryonic stem cells (hESCs) originate from a
unique mesoderm characterized by robust RALDH2 expression. This
study established an atrial differentiation protocol that included the
addition of retinoic acid. Retinoic acid has also been utilized to selec-
tively differentiate hESCs and hiPSCs into aCMs in other studies.6-10
The distinct properties of the atrial and ventricular cardiomyocytes
are determined by the differential expression of unique sets of ion
channels and other proteins that optimize their specific function. Drugs
that target atrial ion channels selectively can therefore produce
differences in pharmacological function in the two chambers. This
atrial-selective pharmacology is of utmost interest in the study and
treatment of atrial-specific diseases such atrial fibrillation (AF), which is
the most common heart rhythm disorder. Investigating atrial-selective
pharmacology can assist and guide novel cardiac drug development as
well as improving both safety and efficacy by avoiding potential toxic
electrophysiologic effects on the ventricular chambers.
The differential pharmacology of stem cell-derived aCMs was
studied previously by Laksman et al7 who showed that flecainide can
rescue the AF phenotype in a dish. Other studies have also studied
the selective pharmacological effects of agents on hiPSC-derived
aCMs but have largely focused on proof-of-concepts using limited
number of test compounds and standard measurement systems that
are low in throughput.9,10 With a focus on translation, a preclinical
model platform that characterizes pharmacological activity must cap-
ture the main cardiac functional signatures that most closely mimic
and predict human cardiac physiology and drug responses. As such,
we established in this study an in vitro assay platform by combining
hiPSC-derived atrial cardiomyocytes (hiPSC-aCMs) and high-content
optical mapping, a noninvasive all-optical system that simultaneously
measures membrane potential (Vm) and Ca
2+ transients at a high-reso-
lution in a monolayer tissue format.
We first demonstrate a selective hiPSC-aCM differentiation pro-
tocol by modifying the well characterized GiWi protocol11 through
the controlled introduction of retinoic acid. The recapitulation of the
human atrial phenotype of the hiPSC-aCMs was validated with assays
that measure the expression of gene transcripts and proteins, as well
as functional signatures. We then demonstrate the utility of our plat-
form as an atrial-selective drug screening tool by using existing clinical
and experimental drugs. The model established in this study adds to
our current understanding of the utility of stem cell-derived
cardiomyocytes in preclinical and translational research focused on
screening new pharmacological agents.
2 | METHODS AND MATERIALS
A detailed methods section is available in the Supplemental
Information.
2.1 | Maintenance and expansion of hiPSCs
hiPSCs (WiCell, IMR90-1) were maintained and expanded in
mTeSR1 medium and feeder-free culture using 6-well plates coated
with Matrigel. Using Versene (EDTA), hiPSCs were passaged every
4 days or 85% confluency at 1:15 ratio. Passaged hiPSCs were
cultured with mTeSR1 supplemented with 10 μM Y27632 for the
first 24 hours and the mTeSR1 was exchanged daily during cell cul-
ture maintenance.
2.2 | Directed differentiation of hiPSCs into atrial
and ventricular subtypes
hiPSC-derived ventricular cardiomyocytes were differentiated by
employing a modified GiWi protocol11 that we previously publi-
shed.12 In brief, hiPSCs were seeded at a density of 87 500 cel-
ls/cm2. At day 0, differentiation was initiated using 12 μM
CHIR99021. At day 3, the cells were incubated with 5 μM IWP-4.
At day 5, the media were refreshed with RPMI-1640 supplemented
with B27 minus insulin. At day 7, the medium was replaced with
cardiomyocyte maintenance media (RPMI-1640 supplemented with
B27 with insulin). Thereafter, cardiomyocyte maintenance media
were replaced every 4 days. For the atrial differentiation protocol,
retinoic acid (RA) addition was first optimized in pilot studies
(Figure S2 and S3) and determined to be 0.75 μM RA every
24 hours from days 4-6.
Significance statement
Current in vitro drug screening systems for treatment of
atrial fibrillation are confounded by cell type heterogeneity,
specificity, and translatability to human physiology. In this
study, we developed a drug screening platform using human
induced pluripotent stem cell-derived atrial cardiomyocytes
(hiPSC-aCMs) and a multiwell optical mapping system. The
high-content optical mapping system reports on membrane
voltage and Ca2+ transients which serve as critical bio-
markers of cardiac function in vitro. The hiPSC-aCMs gener-
ated by this protocol possess atrial-specific molecular
profiles, functional signatures, and pharmacological
response. These findings demonstrate that the platform can
be readily applied as a relevant preclinical model for drug
screening for atrial fibrillation therapies.
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2.3 | Flow cytometry
hiPSC-aCMs and hiPSC-vCMs at Day 20-30 postdifferentiation were
dissociated into single cells as described in the Supplemental Informa-
tion. The harvested cells were fixed in 4.1% PFA solution for 25 minutes
and then washed and permeabilized in Saponin/FBS. Cells were subse-
quently incubated overnight in primary mouse-cTnT (1:2000) and
rabbit-MLC2V (1:1000) antibodies. Subsequently, the cells were washed
and incubated in secondary goat anti mouse Alexa-488 (1:500) and goat
anti rabbit Alexa-647 (1:2000) antibodies for 1 hour, respectively. Cells
were then washed and suspended in PBS for analysis. All analyses were
performed using the BDJAZZ Fluorescence Activated Cell Sorter.
2.4 | mRNA expression profiling
Gene expression profiling was conducted using multiplexed
NanoString and real time quantitative PCR (qPCR). Pooled total RNA
was used in both assays. The extracted RNA was reverse transcribed
into cDNA which was used in the qPCR assay. Oligonucleotide
sequences are described in Table S7. The multiplexed mRNA profiling
was conducted using NanoString Technologies (Seattle, Washington)
platform with a custom Codeset containing 250 gene probes. Analysis
was performed on the Sprint instrument and nSolver analysis soft-
ware with the Advanced Analysis module.
2.5 | Atrial natriuretic peptide measurement
The levels of atrial natriuretic peptide (ANP) of hiPSC-aCMs and
-vCMs were measured by a competitive enzyme-linked immunosor-
bent assay (ELISA) using a commercially available kit (Invitrogen, Cali-
fornia). The assay was conducted according to the manufacturer's
protocol and was measured using a spectrophotometric plate reader.
2.6 | Cardiomyocyte enrichment
For cardiac enrichment, hiPSC-aCMs and -vCMs at day 20-30
postdifferentiation were dissociated into single cells which were then
enriched using a MidiMACS PSC-derived Cardiomyocyte Isolation Kit
(Miltenyi Biotec, Germany) according to the manufacturer's protocol.
Enriched hiPSC-CMs were seeded on Matrigel-coated 24-well plates
at a seeding density of 600 000 cells per well.
2.7 | Patch-clamp recordings
Single hiPSC-aCMs and -vCMs were plated on gelatin (0.1%) and
Geltrex (1:10) at 30 000 cells per well. After 48 hours in culture, glass
electrodes were used to achieve the whole-cell configuration with sin-
gle hiPSC-CMs and only cells with gigaohm seals were used for fur-
ther analysis. The formulation for internal and external recordings
solutions are outlined in the Supplemental Information. Current
recordings were performed using the Axon Instruments 700B ampli-
fier and digitized at 20 kHz. All recordings were performed at
33-35C as maintained. For pacing at 1 Hz, gradually increasing
amounts of current were injected with a 1 ms pulse width until reli-
able action potentials (APs) were triggered. The maximal upstroke
velocity was determined by calculating the maximum derivative and
the resting membrane potential was measured during a 5 second
epoch without spontaneous activity 1 minute after break-in. Further
details on data analysis are found in the Supplemental Information.
2.8 | Optical mapping
Optical mapping recordings were performed on enriched monolayers
of hiPSC-aCMs and -vCMs cultured in a 24-well plate format at Day
45-60 postdifferentiation. Imaging experiments were conducted using
Ca2+ Tyrode's solution (formulation found in Supplemental Informa-
tion). The hiPSC-CMs were loaded with RH-237, blebbistatin, and
Rhod-2AM sequentially before imaging as described.12,13 Both RH-
237 and Rhod-2AM were excited by 530 nm LEDs. Images were
acquired at a frame rate of 100 frames/second by a sCMOS camera
(Orca Flash 4.0V2, Hamamatsu Photonics, Japan) equipped with an
optical splitter. The cells were paced using programmable stimulation.
Data collection, image processing, and initial data analysis were
accomplished using custom software. The multiwell optical mapping
system was custom engineered in the lab based on a system as
described previously.12,13 Further details are found in the Supplemen-
tal Information.
2.9 | Pharmacological analyses
The drugs used in this study are listed Table S8. Drug stocks were fur-
ther diluted in Ca2+ Tyrode's solution prior to pharmacological testing
with the final DMSO concentration in the experimental solution not
exceeding 0.03% (v/v). Drug effects were studied in serum-free condi-
tions (ie, Ca2+ Tyrode's and drug only) at four doses by sequentially
increasing the drug concentration in the same well with recordings at
20-minute intervals.
2.10 | Statistical analysis
Further details on data and statistical analysis can be found in the
Supplemental Information. Unpaired t tests were conducted to com-
pare two groups (ie, hiPSC-aCMs vs hiPSC-vCMs) in the analysis of
qPCR, ELISA, patch clamp recordings, and optical mapping (baseline
condition and normalized drug effects). Analysis of dose-dependent
effects was performed using one-way ANOVA and Dunnett's post
hoc test. All data are presented as mean ± SEM unless noted other-
wise. Significance level for all statistical analysis was set at p < .05
with the following notation: *p < .05, **p < .01, ***p < .001.
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3 | RESULTS
3.1 | RA treatment drives cardiac differentiation
into atrial phenotype
We first optimized the atrial differentiation protocol by altering the
concentration and timing of retinoic acid (RA) based on the molecular
signatures of atrial phenotype as measured by qPCR and flow cyto-
metry (Figures S2 and S3). Higher dose of RA reduced cardiac differ-
entiation efficacy defined by the decrease in the cTnT+ proportion of
the total cell population as measured by flow cytometry (Figure S2A).
The finalized protocol to generate hiPSC-aCMs included RA addition
at 0.75 μM every 24 hours on days 4, 5, and 6 (Figure 1A) which was
found as a balance between sufficiently driving atrial differentiation
as defined by decreased ventricular marker myosin light chain 2 - ven-
tricular paralog (MLC-2v) while having no impact cardiac differentia-
tion efficacy Figures S2 and S3).
Compared with hiPSC-vCMs, hiPSC-aCMs were found to have no
significant difference in pan cardiac phenotype. Expression of the pan
cardiac transcript NKX 2.5 measured by qPCR was similar between
hiPSC-aCMs and -vCMs (Figure 1B), as was cardiac troponin T (cTnT)
protein expression measured by flow cytometry (Figures 1C and S1).
The protein expression of MLC-2v was reduced in hiPSC-aCMs com-
pared with hiPSC-vCMs (8.0 ± 1.1% vs 57.0 ± 0.5%; p < .05)
(Figure 1C). Furthermore, hiPSC-aCMs displayed higher concentra-
tions (increased by 91%) of atrial natriuretic peptide (ANP) at 65 ± 2
compared with 34 ± 6 ng/mL in hiPSC-vCMs as measured by
ELISA (p < .05).
The qPCR assay revealed that atrial-specific transcripts such as
atrial natriuretic peptide (NPPA), connexin 40 (GJA5), the calcium
channel CaV1.3 (CACNA1D), and the K
+ channels Kv1.5 (KCNA5)
and Kir3.1 (KCNJ3) transcripts were all expressed at a significantly
higher levels in hiPSC-aCMs compared with hiPSC-vCMs (p < .05,
Figure 1B). Another ventricular marker, IRX4, also had decreased
expression in hiPSC-aCMs (Figure 1B). Furthermore, consistent
with previous studies,8-10,14,15 hiPSC-aCMs started beating at day
10 or earlier and exhibited an increased beating frequency relative
to hiPSC-vCMs, which started beating around day 10-12
postdifferentiation.
3.2 | Gene expression analysis of hiPSC-aCMs
We performed an extensive gene expression analysis of hiPSC-aCMs
and -vCMs using NanoString technology in which each mRNA copy
was digitally counted for accurate and sensitive detection of gene
expression.16 Five independent differentiation batches of each cardiac
subtype were included in the analysis. The unsupervised hierarchical
clustering analysis showed clear grouping of hiPSC-aCM samples that
were segregated relative to hiPSC-vCMs (Figure 2A). The gene
expression profile of the hiPSC-vCM samples were more variable with
2 samples closer in distance to the hiPSC-aCMs while three samples
displayed clear segregation (Figure 2A). The overall difference in
global gene expression and lineage between hiPSC-aCMs and -vCMs
was also captured in the principal component analysis (PCA,
Figure S4A). Out of the 250 transcripts analyzed, 200 genes were
detected above background noise defined by a threshold of 50 raw
digital counts as determined by the negative controls of the assay. In
the hiPSC-aCMs, 14 and 27 genes were significantly upregulated and
downregulated, respectively (Figure 2C). As expected, hiPSC-aCMs
displayed significantly higher expression profiles of atrial-specific
markers including atrial-specific K+ channel Kv1.5 (KCNA5) and tran-
scription factors (NR2F2 and TBX18) (Figure 2C). Meanwhile, hiPSC-
vCMs displayed higher expression of ventricular-specific genes such
as those encoding for contractile proteins MYL2, MYH7, and the L-
type Ca2+ channel isoform Cav1.2 (CACNA1C) (Figure 2C). The genes
encoding for the proteins in the sarcoplasmic reticulum complex such
as TRDN, CASQ2, and RYR2 were expressed in significantly lower
amounts in the hiPSC-aCMs samples (Figure 2C). Meanwhile, pan-
cardiac markers NKX2-5 and TNNT2 were expressed at similar levels
in both hiPSC-aCMs and -vCMs, further corroborating the efficiency
of the differentiation protocol (Figure S4B).
3.3 | Functional phenotyping of hiPSC-derived
atrial cardiomyocytes
We compared the electrophysiological characteristics of the differ-
entiated hiPSC-aCMs and -vCMs using whole-cell patch clamp.
Confirming our observations in tissue culture, the spontaneous
beating rates were higher in the single hiPSC-aCMs than in -vCMs
(Figure 3A,C). Whole cell current clamp recordings demonstrated
the ventricular-like AP morphology of hiPSC-vCMs with a clear and
prolonged plateau phase while the AP of the hiPSC-aCMs displayed
atrial-like morphology with a shorter action potential duration
(APD) and a lack of prolonged plateau phase at both spontaneous
beating rates (Figure 3B,D, left panel) and paced at 1 Hz
(Figure 3B,D, right panel). No statistical differences were observed
in the resting membrane potential and the maximum upstroke
velocity of hiPSC-aCMs and -vCMs. The APD at 50% (APD50) and
90% (APD90) of the peak voltage were significantly shorter in
hiPSC-aCMs than -vCMs at both spontaneous beating rates
(APD50: 157 ± 16 ms vs 349 ± 35 ms, p-value <.005; APD90:
249 ± 34 ms vs 484 ± 30 ms, p-value <.005) and paced at 1 Hz
(APD50: 157 ± 16 ms vs 264 ± 44 ms, p-value <.05; APD90:
242 ± 22 ms vs 341 ± 48 ms, p-value <.05).
We further assessed the functional properties of hiPSC-aCMs and
-vCMs using optical mapping with simultaneous measurement of APs
and calcium transients (CaT). Like the patch clamp recordings, optical
membrane voltage measurements revealed similar atrial-like and
ventricular-like AP morphology in the hiPSC-aCMs and -vCMs, respec-
tively (Figure 4A). AP and CaT durations were quantified at early, mid,
and late repolarization (APD20, APD50, and APD80) and Ca
2+ decay
(CaTD20, CaTD50, and CaTD80), respectively. These stages reflect dif-
ferent phases of ionic currents across the plasma membrane and the
extrusion of Ca2+ handling mechanics.
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For these experiments, both hiPSC-aCMs and -vCMs were paced
at 1 Hz. All measured levels of the APD were significantly shorter in
hiPSC-aCMs compared with hiPSC-vCMs (APD20: 84 ± 8 ms vs
127 ± 6 ms, p < .05; APD50: 131 ± 12 ms vs 191 ± 8 ms, p < .01;
APD80: 179 ± 16 ms vs 251 ± 12 ms, p < .05; Figure 4D). The overall
CaTD of hiPSC-aCMs was significantly shorter than that of hiPSC-
vCMs (CaTD20: 180 ± 12 ms vs 266 ± 12 ms, p < .001; CaTD50:
282 ± 18 ms vs 397 ± 16 ms, p < .001; CaTD80: 474 ± 27 ms vs
615 ± 18 ms, p < .001; Figure 4E). Compared with hiPSC-vCMs,
hiPSC-aCMs displayed significantly faster CaT time-to-peak (hiPSC-
F IGURE 1 Directed differentiation of hiPSC-derived atrial and ventricular CMs. A, Schematic depicting the atrial differentiation protocol.
Doses of 0.75 μM retinoic acid (RA) were added to the cells every 24 hours on days 4, 5, and 6 with media exchanged to RPMI1640 + B27 with
insulin at day 7. Cells were harvested for analysis at day 20. B, qPCR analysis of ventricular markers MYL2 and IRX4, cardiac marker NKX2.5, and
atrial markers NPPA, GJA5, CACNA1D, KCNA5, and KCNJ3. n = 3, unpaired t test, *p < .05. C, Flow cytometric analysis of cardiac troponin T (cTnT)
and myosin light chain 2v (normalized to cTnT expression) in hiPSC-aCMs and -vCMs. n = 4, unpaired t test, ***p < .001. D, Average beating rates
of hiPSC-aCMs and -vCMs from the day they begin to beat until day 20. n = 4 independent differentiation batches. E, Atrial Natriuretic peptide
(ANP) concentration between hiPSCs, and hiPSC-aCMs and -vCMs determined by competitive ELISA. n = 3 and n = 2 hiPSC lines, unpaired t test
*p < .05, **p < .01, ***p < .001. Data are presented as mean ± SEM One n represents one independent differentiation batch
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aCMs: 116 ± 7 ms vs hiPSC-vCMs: 246 ± 10 ms, p < .05) and faster
decay kinetics (τ; hiPSC-aCMs: 350 ± 39 ms vs hiPSC-vCMs:
671 ± 118 ms, p < .05) indicating that Ca2+ handling mechanics are
accelerated in hiPSC-aCMs (Figure 4F,G).
The direct comparison between whole-cell patch clamp and opti-
cal mapping read-outs paced at 1 Hz is shown in Figure S7. We
observed no differences in the read-outs of hiPSC-aCMs at APD20
(optical: 84 ± 8 ms, patch: 98 ± 12 ms) and APD50 (optical:
131 ± 12 ms, patch: 169 ± 19 ms). However, APD80 of hiPSC-aCMs
measured by patch clamp was longer than the optical APD80
(253 ± 22 ms vs 179 ± 16 ms, p < .05). Similarly, both APD20
(216 ± 22 ms vs 127 ± 6 ms) and APD80 (393 ± 62 vs 251 ± 12 ms) of
hiPSC-vCMs measured by patch clamp were longer than the compara-
ble optical measurements. APD50 of hiPSC-vCMs did not show a sta-
tistical difference between the two assays (optical: 191 ± 8 ms, patch:
308 ± 60 ms).
F IGURE 2 Gene expression analysis of hiPSC-aCMs and -vCMs using NanoString. Global gene expression pattern of hiPSC-aCMs and -vCMs
shown in A, heat map of the expression of the 250 genes across samples of hiPSC-aCMs and -vCMs. The cluster dendrogram shows the
unsupervised hierarchical clustering that was conducted using the agglomerative algorithm and the Euclidian distance criterion. B, Differentially
expressed genes between hiPSC-aCMs and -vCMs expressed in volcano plot shows 14 upregulated (red) and 27 downregulated (blue) genes in
hiPSC-aCMs. Solid horizontal line represents the Benjamini-Hochberg false discovery rate (FDR) adjusted p-value <.05 (−log10 = 1.3). Dashed
vertical lines represent the arbitrary log2 fold change cut-off of −0.5 and 0.5. C, Forty-two differentially expressed genes identified from the
statistical criteria of FDR adjusted p-value <.05 and log2 fold change of <−0.5 and >0.5. Data are presented as mean ± SEM. n = 5 independent
differentiation batches
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Rate-dependent properties are critical in cardiac function. A vari-
able rate protocol (Figure S6) in which the hiPSC-CMs were electri-
cally paced with increasing frequency at every cycle was used to
investigate the electrical restitution dynamics. The electrical restitu-
tion curve reflects the ability of the cardiac system to accommodate a
higher pacing rate by progressive shortening of APD80 and is
described as APD80 in relation to the diastolic interval (DI). Compared
with hiPSC-vCMs, the electrical restitution curve of the hiPSC-aCMs
displayed a flatter portion and did not show APD80 shortening at lon-
ger diastolic intervals (Figure 4F). The extensive shortening in APD80
started at shorter diastolic intervals for hiPSC-aCMs (<275 ms)
compared with hiPSC-vCMs (<500 ms). The maximum slope of the
restitution curve was higher in hiPSC-vCMs compared with hiPSC-
aCMs (1.26 ± 0.08 vs 0.91 ± 0.04, p < .05; Figure 4G) indicating faster
kinetics of APD in response to higher pacing rate.
3.4 | In vitro screening for atrial-selective
pharmacology
We first established the utility of optical mapping to detect a pan-
cardiac pharmacological response by using dofetilide, a strong blocker
F IGURE 3 hiPSC-aCMs and -vCMs have distinct electrophysiological characteristics. Single differentiated hiPSC-aCMs and -vCMs were
plated on gelatin and Geltrex after 30 days in culture. A, Whole cell current clamp recordings from a spontaneously beating hiPSC-vCM. B,
Recorded action potential (APs) demonstrates typical prolonged plateau phase in both spontaneous (left) and/or paced at 1 Hz (right). C, Current
clamp recording from a spontaneously beating hiPSC-aCM. D, Single AP from hiPSC-aCM demonstrates shortened action potential duration
(APD) and lack of prolonged plateau phase, spontaneous (left), paced at 1 Hz (right). E, The first differential of voltage recordings from hiPSC-
aCMs and -vCMs were used to calculate the maximal upstroke velocities. F, One minute after achieving the whole-cell configuration, the average
resting membrane potential was measured. G, Spontaneously beating and 1 Hz paced APs were assessed for duration at 50% of peak (APD50),
and H, 90% of peak (APD90). Statistics were performed by unpaired t test. *p < .05, ***p < .005. Data are presented as mean ± SEM. Two
differentiation batches were included in this analysis
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of the rapid delayed rectifier K+ current (IKr),
17 an ionic current
expected to be present in both hiPSC-aCMs and -vCMs.18 Dofetilide
elicited a dose-dependent response in both hiPSC-aCMs and -vCMs.
Compared with predrug baseline, dofetilide at 100 nM prolonged
APD80 of both hiPSC-aCMs from 182 ± 16 ms to 355 ± 24 ms (95
+ 7% prolongation) and of hiPSC-vCMs from 238 ± 20 ms to
319 ± 45 ms (34 ± 14% prolongation, p < .05; Table S1 and
Figure 5C). The drug prolonged early-repolarization (APD20) of hiPSC-
vCMs at 10 and 30 nM while having no effect on APD20 of hiPSC-
aCMs at all tested doses (Table S1). Additionally, CaTD50 and CaTD80
of both hiPSC-aCMs and -vCMs were significantly prolonged in
response to dofetilide (Table S1). However, hiPSC-aCMs appeared to
be more sensitive to dofetilide as the APD80 was significantly pro-
longed at the lowest tested dose of 3 nM (from to 182 ± 26 ms to
241 ± 26 ms, p < .05; Table S1) and displayed a larger dose-response
(Figure S8).
Next, we demonstrated the functional differences in the ion
channel profiles of hiPSC-aCMs and -vCMs. We aimed to show that
the ultrarapid outward current (IKur) produced by the channel Kv1.5
(KCNA5) was functional and specific to hiPSC-aCMs, while the inward
Ca2+ current (ICa,L) produced the voltage-dependent L-type Ca
2+ chan-
nel CaV1.2 (CACNA1C) was functional and specific to hiPSC-vCMs.
We used two relatively selective compounds, 4-aminopyridine (4AP)
and nifedipine, to dissect the presence of functional IKur and ICaL,
F IGURE 4 Functional phenotyping of hiPSC-derived atrial and ventricular CMs using optical mapping. Representative average traces of A,
action potential and B, Ca2+ transients of hiPSC-aCMs and -vCMs electrically paced at 1 Hz. C, Electrical restitution curve measured at APD80
relative to the diastolic interval (DI). D, Quantification of early- (APD20), mid- (APD50), and late- (APD80) repolarization, unpaired t test, *p < .05,
**p < .01. E, Quantification of early- (CaTD20), mid- (CaTD50), and late- (CaTD80) Ca
2+ transient decay, unpaired t test, ***p < .001. F, Time to peak
(TTP) of the Ca2+ transient, unpaired t test, ***p < .001. G, Time constant (τ) of Ca2+ decay, unpaired t test *p < .05. H, Maximum slope of the
electrical restitution as shown in panel C, unpaired t test, *p < .05. Electrical restitution curves were measured under a variable rate pacing
protocol (60-200 bpm) as described in the Supplemental Information. n = 4 (four independent differentiation batches) and cardiac enriched
hiPSC-aCMs and -vCMs were analyzed in these set of experiments. Data are presented as mean ± SEM
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respectively. While nifedipine is also known to block Cav1.3, it is
expected to have a preferential effect at lower concentrations on
CaV1.2 based on the literature which indicates 13-fold higher block
on CaV1.2 than CaV1.3.
19
At the highest tested dose (300 nM), nifedipine significantly
decreased APD50 of hiPSC-vCMs from 170 ± 14 ms to 121 ± 16 ms
(28 ± 4% shortening) and decreased CaTD50 from 357 ± 10 ms to
333 ± 23 ms (30 ± 3% shortening) (Figure 5D; Table S2). We observed
a trend in APD50 shortening of hiPSC-aCMs in response to increasing
the nifedipine dose, but the drug elicited a significantly stronger dose-
dependent shortening in both APD and CaTD of hiPSC-vCMs com-
pared with hiPSC-aCMs (Figures S8 and S9). Observing the percent
change from predrug control, nifedipine induced differential response
in overall APD and CaTD between hiPSC-aCMs and -vCMs at
10, 100, and 300 nM (Figure 5D).
In hiPSC-aCMs, 4AP prolonged APD and CaTD in a dose-
dependent manner with a statistically significant change starting at
30 μM (Figure 6A,C; Table S3). 4AP significantly prolonged early-
repolarization (APD20) of hiPSC-aCMs by 46 ± 2% and 66 ± 2% at
50 and 100 μM, respectively (APD20 at baseline: 82 ± 8, at 50 μM:
F IGURE 5 The effects of dofetilide and nifedipine on action potential and Ca2+ transient of hiPSC-aCMs and -vCMs. Representative traces of
action potential and Ca2+ transients illustrating the effects of A, dofetilide and B, nifedipine on hiPSC-aCMs and -vCMs. Higher drug doses are
presented by a progressively darker shade. The effects of C, 4-aminopyridine and D, nifedipine on normalized (percent change from predrug
baseline) action potential duration (APD) and Ca2+ transient duration (CaTD); both parameters being measured at 20%, 50%, and 80%. Dashed
line is the normalized predrug control presented as 0% change. n = 6 from six independent differentiation batches. hiPSC-derived atrial
cardiomyocytes (aCMs) are shown in red while hiPSC-derived ventricular cardiomyocytes (vCMs) are presented in blue. Data are presented as
mean ± SEM. Drug effects were compared between hiPSC-aCMs and -vCMs at each dose using unpaired t test, *p < .05, **p < .001, ***p < .001.
NS stands for not significant
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120 ± 9 ms, at 100 μM: 131 ± 9 ms, p < .05) (Figure 6C and Table S3).
In contrast, 4AP prolonged APD20 of hiPSC-vCMs by 23 ± 4% (APD20
at baseline: 138 ± 8 ms, at 100 μM: 170 ± 9 ms) at the highest tested
dose of 100 μM (Figure 6C and Table S3). hiPSC-aCMs showed greater
change in APD to relative to predrug control at all concentrations of
4AP compared with hiPSC-vCMs (Table S3), This is corroborated by
the steeper trend of the dose response relationship in hiPSC-aCMs
(Figure S8). Additionally, the overall CaTD of hiPSC-aCMs were pro-
longed after exposure to 4AP at 10 μMwhile the drug had a significant
effect on CaTD of hiPSC-vCMs at 30 μM (CaTD50 elongation from
baseline: 68 ± 2% vs 12 ± 2%, p < .05) (Table S3).
We then demonstrated the effectiveness of our drug screening
platform in assessing the effects of experimental compounds designed
to have targeted effects on atrial-specific ion channels using
AVE0118 and UCL1684.
AVE0118 is an experimental drug that blocks IKur, the G-protein-
activated K+ current (IKAch), and the transient outward K
+ current (Ito)
at a similar dose range.20 Both IKur and IKAch are atrial-specific ionic
currents. AVE0118 prolonged mid- and late- repolarization (APD50
and APD80) of both hiPSC-aCMs and -vCMs at the two highest tested
doses (3 and 10 μM; Table S4). Similarly, AVE0118 had significant
effects on CaTD50 and CaTD80 of hiPSC-aCMs and -vCMs at all
F IGURE 6 The effects of 4-aminopyridine (4AP) and AVE0118 on action potential and Ca2+ transient of hiPSC-aCMs and -vCMs.
Representative traces of action potential and Ca2+ transients illustrating the effects of A 4-aminopyridine (4AP) and B, AVE0118 on hiPSC-aCMs
and -vCMs. Higher drug dose is presented by a progressively darker shade. The effects of C dofetilide and D, vernakalant on normalized (percent
change from predrug baseline) action potential duration (APD), and B, Ca2+ transient duration (CaTD); both parameters being measured at 20%,
50%, and 80%. Dashed line is the normalized predrug control presented as 0% change. n = 6 from six independent differentiation batches. hiPSC-
derived atrial cardiomyocytes (aCMs) are shown in red while hiPSC-derived ventricular cardiomyocytes (vCMs) are presented in blue. Data are
presented as mean ± SEM. Drug effects were compared between hiPSC-aCMs and -vCMs at each dose using unpaired t test, *p < .05, **p < .001,
***p < .001. NS stands for not significant
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tested doses (Table S4). However, the APD50 and APD80 of hiPSC-
aCMs were significantly prolonged at a lower dose of 1 μM (control:
200 ± 14 ms, 1 μM: 244 ± 16 ms; Table S4). Furthermore, the atrial-
selective effects of the drug were demonstrated by a larger propor-
tional prolongation in APD50 and APD80 of hiPSC-aCMs compared
with hiPSC-vCMs at 1, 3, and 10 μM (APD; Figure 6D). Furthermore,
AVE0118 induced a larger proportional prolongation in CaTD of
hiPSC-aCMs compared with hiPSC-vCMs at all tested doses
(Figure 6D). Early repolarization (APD20) of hiPSC-aCMs also dis-
played a large dose-dependent response (Figure S8) with a
proportionally larger prolongation at 10 μM (63 ± 2% vs 43 ± 5%,
p < .05; Figure 6D).
UCL1684 is purported to be a potent direct pore blocker of the
small conductance Ca2+ activated K+ channel (SK channel)21 and was
expected to induce a dose-dependent atrial-selective response. In
hiPSC-aCMs, UCL1684 treatment resulted in a significantly prolonged
APD80 at 3 and 10 μM (from predrug control: 136 ± 11 ms to 3 μM:
188 ± 25 ms or 38 ± 5% prolongation, and to 10 μM: 206 ± 32 ms or
49 ± 11% prolongation, p < .05; Figure 7C and Table S5). UCL1684
prolonged CaTD80 of hiPSC-aCMs at all tested doses (baseline:
F IGURE 7 The effects of UCL1684 and vernakalant on action potential and Ca2+ transient of hiPSC-aCMs and -vCMs. Representative Vm
and Ca2+ transients illustrating the effects of A, UCL1684 and B, vernakalant on hiPSC-aCMs and -vCMs. Higher drug doses are presented by a
progressively darker shade. The effects of C, AVE0118 and D, UCL1684 on normalized (percent change from predrug baseline) action potential
duration (APD) and Ca2+ transient duration (CaTD); both parameters being measured at 20%, 50%, and 80%. Dashed line is the normalized
predrug control presented as 0% change. n = 6 from six independent differentiation batches. hiPSC-derived atrial cardiomyocytes (aCMs) are
shown in red while hiPSC-derived ventricular cardiomyocytes (vCMs) are presented in blue. Data are presented as mean ± SEM. Drug effects
were compared between hiPSC-aCMs and -vCMs using unpaired t test at each dose, *p < .05, **p < .001, ***p < .001. NS stands for not
significant
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300 ± 15 ms, at 0.3 μM: 372 ± 23 ms, at 1 μM: 387 ± 33 ms, at 3 μM:
413 ± 24 ms, at 10 μM: 416 ± 39 ms, p < .05; Table S5). In contrast,
UCL1684 exposure showed no statistically significant effect on over-
all APD and CaTD of hiPSC-vCMs. The sensitivity of hiPSC-aCMs to
UCL1684 was also reflected in the dose-response relationship show-
ing a prolongation APD80, in contrast to the minimal prolongation in
APD80 of hiPSC-vCMs (Figure S8).
Finally, we tested the effects of vernakalant which is a multi-ion
channel blocker that blocks the fast and late inward Na+ current (INa,
INaL, respectively), the IKur, and the IKAch.
22 The drug is used clinically
for intravenous cardioversion of patients in AF23 and was expected to
induce an atrial-specific effect due to its IKur and IKAch blocking
properties.
Vernakalant elicited a positive dose-dependent response in both
APD and CaTD of hiPSC-aCMs with minimal measurable effects on
hiPSC-vCMs (Table S6; Figures S8 and S9). Vernakalant demonstrated
atrial-selectivity with statistically significant differences between APD
and CaTD of hiPSC-aCMs and -vCMs at doses of 3, 10, and 30 μM
(Figure 7D). Compared with APD at baseline, vernakalant at 10 μM
significantly prolonged APD20, APD50, and APD80 of hiPSC-aCMs by
84 ± 6%, 70 ± 5%, and 77 ± 4%, respectively (Figure 7D). Additionally,
vernakalant at 10 μM prolonged CaTD20, CaTD50, CaTD80 of hiPSC-
aCMs by 58 ± 4%, 50 ± 3%, 35 ± 5%, respectively (Figure 7D). At clin-
ically relevant concentrations (30 μM), vernakalant greatly affected
early repolarization of hiPSC-aCMs (APD20 prolonged by 124 ± 8%;
Figure 7D). At 30 μM, vernakalant prolonged APD80 of hiPSC-vCM by
20 ± 7% (APD80: 238 ± 22 ms at baseline vs 289 ± 30 ms at 30 μM,
p < .05; Figure 7D and Table S6). Except for APD80 prolongation at
30 μM, vernakalant had no statistically significant effect on overall
APD and CaTD of hiPSC-vCMs at the lower doses (Table S6).
4 | DISCUSSION
In this study, we were successful in efficiently differentiating hiPSCs
into a monolayer of cardiomyocytes with an atrial phenotype by modi-
fying the GiWi protocol.11 We used multiple phenotypic approaches
such as qPCR, digital multiplexed gene expression analysis with
NanoString technology, flow cytometry, ELISA, voltage measurements
with current clamp electrophysiology as well as simultaneous voltage
and Ca2+ transient measurements with optical mapping to demon-
strate a clear and distinct atrial phenotype. Unique to our study, we
completed an in-depth pharmacological analysis with simultaneous
voltage and Ca2+ measurements to demonstrate the differential
responses of these chamber-specific cardiomyocytes, and their utility
as a translational model in screening for the safety and efficacy of
novel atrial-specific compounds for the treatment of AF.
Our observations support previous data in showing that atrial
specification is in part mediated by RA.6,8-10,16 In our protocol, atrial
differentiation was accomplished by adding 0.75 μM RA 24 hours
after WNT inhibition, with a total exposure time of 72 hours. The gen-
erated hiPSC-aCMs showed an atrial-specific phenotype as validated
at both protein and transcript levels with a decrease in ventricular-
specific and an increase in atrial-specific markers. These results sug-
gest that RA, at the dose and temporal exposure used in this study,
maintains cardiac differentiation efficiency while pushing the differen-
tiation process into an atrial lineage.
As a complementary assay, we used the NanoString digital multi-
plexed gene expression analysis to assess the expression of 250 genes
custom-curated from the existing literature. We found MYL2 and
MYH7, markers of the ventricular phenotype, to be significantly differ-
entially expressed between hiPSC-aCMs and -vCMs, matching the
gene expression pattern of native adult human right atrial and left
ventricular tissues.24 Another ventricular-specific marker KCNA425
which encodes for the Kv1.4 channel of the slow Ito was down-
regulated in hiPSC-aCMs. Canonical atrial markers such as KCNA5 and
NR2F2 were also confirmed to be differentially upregulated in hiPSC-
aCMs. Other markers of human atrial specificity such CXCR4, GNAO1,
JAG1, PLCB1, and TBX18 as retrieved from the GTEx database26 were
upregulated in our hiPSC-aCMs further demonstrating the effect of
RA on driving the differentiation pathway into an atrial lineage.
MYL7, thought to be an atrial-specific marker, was not found to
have a significantly higher expression in hiPSC-aCMs. The differential
expression of MLC-2a may however require additional maturation of
the hiPSC-CMs. Other studies11,27 have shown a high expression in
MLC-2a at day 20 postdifferentiation and a subsequent decrease over
time in culture systems generating predominantly ventricular hiPSC-
CMs. One study has shown a higher expression of MLC-2a in hiPSC-
aCMs analyzed at a later date (earliest at day 60).6
Electrophysiological differences between atrial and ventricular
phenotypes, in terms of voltage and Ca2+ handling, define their func-
tion and are critical to the development and determination of efficacy
of atrial-specific compounds. As demonstrated by whole-cell patch
clamp and optical mapping measurements, the hiPSC-aCMs generated
in this study exhibited atrial-like AP and Ca2+ handling properties.
Namely, the AP of hiPSC-aCMs was significantly shorter, along with a
lack of a prolonged plateau phase as opposed to the AP of hiPSC-
vCMs, an observation that is aligned with native cardiomyocyte elec-
trophysiology.28 Similarly, the CaT of hiPSC-aCMs had faster kinetics
with a faster decay time as reflected by the differential expression of
Ca2+ channel isoforms, further demonstrating the differential physiol-
ogy between hiPSC-aCMs and -vCMs.
In terms of APD measurements, we observed a good correlation
between the patch clamp and optical mapping recordings for hiPSC-
aCMs. In hiPSC-vCMs, however, the optical AP measurements were
shorter overall than patch clamp recordings. This discrepancy may
be attributed to the heterogeneity of our current ventricular differ-
entiation protocol which generated predominantly ventricular
cardiomyocytes but also contain a small proportion of non-
ventricular phenotypes (ie, atrial myocytes and nodal cells). Thus,
the optical AP signals represents an average from about 300 000
cells in each 1 cm2 region of interest.
Another hallmark of cardiomyocyte function is rate-dependence,
as described by the electrical restitution curve.29 We observed that
the electrical restitution properties were different between hiPSC-
aCMs and -vCMs. Compared with hiPSC-vCMs, hiPSC-aCMs
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displayed a steady-state-like property by undergoing minimal APD80
shortening in response to the lower ranges of the pacing protocol
(cycle lengths of about 400-1000 ms) indicating full recovery of ion
channel kinetics at these pacing ranges. In contrast, the hiPSC-vCMs
displayed consistent APD80 shortening at the same pacing range. It is
important to note that APD restitution curves are likely different
when using the standard steady-state extra stimulus protocol com-
pared with dynamic pacing, particularly in cardiomyocytes with imma-
ture Ca2+ handling and memory.29 In relation to dynamic pacing
protocol, hiPSC-vCMs have steeper maximum slope of the restitution
curve compared with hiPSC-aCMs as steady-state APD is the princi-
pal determinant of the slope of the ventricular restitution curve.30
The presence of specific ion channel currents (ie, IKur, IKAch, and
ICaL) explain, in part, the functional differences between the two car-
diac chamber subtypes, the expressions of which were already shown
in our qPCR and NanoString assays. We used a series of compounds
(4-aminopyridine, dofetilide, vernakalant, AVE0118, UCL1684, and
nifedipine) to demonstrate the function of atrial-specific ionic currents
in our model system and were able to show the expected chamber
specific differences between hiPSC-aCMs and -vCMs.
Dofetilide (DF) served as a positive control in our optical mapping
assay as a clinically relevant drug which has a strong effect on IKr in
both atria and ventricular CM.31 As expected, dofetilide affected the
repolarization of both hiPSC-aCMs and -vCMs, confirming the pres-
ence of IKr in both cell types. At clinically relevant doses of DF (3 and
10 nM), hiPSC-aCMs displayed greater sensitivity to the drug indicat-
ing a larger proportional contribution of IKr in the AP of hiPSC-aCMs
relative to hiPSC-vCMs. This may partly explain the effectiveness of
the drug in the clinical treatment of AF. However, clinical use of the
drug to treat AF is limited due to its tendency to induce QTc prolon-
gation. This pro-arrhythmic risk of TdP32 which was captured by the
prolongation of APD80, an in vitro surrogate of QTc, in the hiPSC-
vCMs. This finding supports the utility of our optical mapping assay in
predicting the risk of ventricular proarrhythmia in vitro.
The compound 4AP has been shown to selectively block Kv1.4
(Ito) and Kv1.5 (IKur)
33 and is therefore expected to elicit a response in
hiPSC-aCMs at lower doses than in hiPSC-vCMs as IKur (Kv1.5) is a
strong functional indicator of atrial phenotype. Confirmation of the
atrial expression of IKur channels was demonstrated by the stronger
dose-dependent hiPSC-aCM AP prolongation to 4AP at all tested
doses (10, 30, 50 and,100 μM) suggesting selective sensitivity of
hiPSC-aCMs to 4AP due to a greater expression of Kv1.5. The inhibi-
tory effects of 4AP were observed at higher doses (50 and 100 μM) in
hiPSC-vCMs which can be attributed to the heterogeneous popula-
tion, potential off-target effects at these high doses, as well as base-
line expression of Kv1.4 (Ito).
Using nifedipine, we demonstrated the functional differences in
Ca2+ handling dynamics between hiPSC-aCMs and -vCMs. Nifedipine
elicited a dose-dependent response in hiPSC-vCMs demonstrating
high sensitivity at 300 nM thereby confirming the functional presence
of Cav1.2. In contrast, hiPSC-aCMs were relatively insensitive to
nifedipine showing no statistically significant differences in APD at all
tested doses. This finding is further corroborated by the relatively
decreased expression of CACNA1C (Cav1.2) in the hiPSC-aCMs. This
suggests that Ca2+ handling in hiPSC-aCMs may be reliant on other
voltage-gated Ca2+ channels such as Cav1.3, as this Ca
2+ channel is
blocked less potently by nifedipine.34 Moreover, our qPCR assay con-
firmed that hiPSC-aCMs had higher expression of CACNA1D (Cav1.3).
AVE0118 is an experimental K+ channel blocker (Ito, IKur, and IKr)
that was predicted to demonstrate targeted effects in hiPSC-aCMs.
However, only a nuanced atrial specificity was observed in our assay.
Although the effects were proportionally larger in hiPSC-aCMs,
AVE0118 prolonged early repolarization of both hiPSC-aCMs and
-vCMs in a similar fashion. The drug prolonged mid- and late-
repolarization at a lower dose (1 μM) in hiPSC-aCMs showing minimal
atrial specific effects. Interestingly, AVE0118 greatly affected Ca2+
handling in hiPSC-aCMs compared with hiPSC-vCMs with larger pro-
portional prolongation of CaTD50 at all doses. These results were
unexpected as AVE0118 is thought to be highly specific to hiPSC-
aCMs due to its IKur blocking component. Perhaps the observed
mixed-effects in both cell types is due to the drug binding to Ito (IC50:
3.4 μM) and IKr (IC50: 9.6 μM)35 which prolongs APD at the tested
doses of 3 and 10 μM as genes encoding the channels producing the
Ito (KCNA4) and IKr (KCNH2) were expressed in our hiPSC-vCMs. The
drug was also shown to be effective in terminating certain ventricular
arrhythmias36 which was predicted based on our results of prolonga-
tion in the APD of hiPSC-vCMs.
Next, we used UCL1684, a highly specific SK channel pore
blocker, to assess the presence of functional SK channels in hiPSC-
aCMs. The SK channel has three paralogs but the SK3 channel variant
(KCNN3) has been shown to be atrial-specific and has been implicated
in AF pathogenesis in several studies.37,38 In this study, UCL1684 dis-
played high specificity toward hiPSC-aCMs with a strong dose-
dependent response. The drug confirmed the presence of functional
SK channels in hiPSC-aCMs at 3 μM with a positive dose-dependent
response while having no effect on hiPSC-vCMs at all tested doses
(0.3, 1, 3, and 10 μM).
Vernakalant is touted as an atrial-selective compound clinically
approved for intravenous cardioversion of AF.39 Strikingly, out of all
the tested drugs, vernakalant showed the most pronounced atrial-
selective effects even though it is a blocker of multiple ion channels
(INa, IKur, and IK,Ach). Vernakalant prolonged APD and CaTD of hiPSC-
aCMs at three tested doses (3, 10, 30 μM). However, no statistically
significant changes were observed in hiPSC-vCMs at early- and mid-
repolarization while the slight prolongation at APD80 at the clinically
relevant dose (30 μM) may be attributed to the INa blocking compo-
nent of vernakalant. This result further demonstrates the sensitivity of
the assay in establishing atrial-selective drug effects.
This study has several limitations. One limitation in our findings is
that we cannot directly compare the results from qPCR and
NanoString as both assays have fundamental differences in technical
principles and statistical methodologies. Taken together, however,
both assays show the global changes in cell type specific gene markers
and further validate the role of retinoic acid in directing the cardiac
differentiation process toward an atrial lineage. The main limitation in
this field is the maturation state of the hiPSC-CMs as they have an
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overall immature phenotype with some crucial differences compared
with adult cardiomyocytes.40 Nonetheless, we were able to observe
the stark differences in genetic, protein, as well as functional signa-
tures of AP and CaT in the two generated chamber-specific cell types.
Additionally, maturation stage does not explain the differences in
chamber-specific phenotype as parallel batch differentiation and time-
in-culture were incorporated in our study design. Most importantly,
we were able to capture effects of drugs that were expected to have
atrial-specific properties in hiPSC-aCMs.
5 | CONCLUSION
The ability to differentiate hiPSC-aCMs provides a unique opportunity
to study atrial physiology and its pharmacologic responses in a
human-relevant in vitro model. We demonstrated an hiPSC-based
in vitro model that recapitulates the molecular and functional charac-
teristics of the phenotype of native atrial tissue. Our platform adds to
the repertoire of cardiac drug screening and can be readily applied in
future efforts of atrial-specific drug discovery.
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